Financial toxicity: a potential side effect of prostate cancer treatment among Australian men
Open accessThe DOI matches its Crossref record.
Abstract
The purpose of this study was to understand the extent, nature and variability of the current economic burden of prostate cancer among Australian men. An online cross-sectional survey was developed that combined pre-existing economic measures and new questions. With few exceptions, the online survey was viable and acceptable to participants. The main outcomes were self-reported out-of-pocket costs of prostate cancer diagnosis and treatment, changes in employment status and household finances. Men were recruited from prostate cancer support groups throughout Australia. Descriptive statistical analyses were undertaken. A total of 289 men responded to the survey during April and June 2013. Our study found that men recently diagnosed (within 16 months of the survey) (n = 65) reported spending a median AU$8000 (interquartile range AU$14 000) for their cancer treatment while 75% of men spent up to AU$17 000 (2012). Twenty per cent of all men found the cost of treating their prostate cancer caused them 'a great deal' of distress. The findings suggest a large variability in medical costs for prostate cancer treatment with 5% of men spending $250 or less in out-of-pocket expenses and some men facing very high costs. On average, respondents in paid employment at diagnosis stated that they had retired 4-5 years earlier than planned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay
Gordon, L. G., Merollini, K. M. D., Lowe, A., & Chan, R. J. (2017) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-016-0204-x · Cited by 479
Self-citationWitte, J., Mehlis, K., Surmann, B., Lingnau, R., Damm, O., Greiner, W., & Winkler, E. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz140 · Cited by 271
Financial toxicity and employment status in cancer survivors. A systematic literature review
Mols, F., Tomalin, B., Pearce, A., Kaambwa, B., & Koczwara, B. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05719-z · Cited by 187
“All were published between 1990 and 2019 and originated from the USA (N = 16), Australia (N = 6), the Netherlands (N = 2), Canada (n = 1), Japan (N = 1), Singapore (N = 1), Iran (N = 1), the UK (N = 1), Germany (N = 1), or Ireland (N = 1).”
BackgroundInfluentialThe economic impact of cancer diagnosis to individuals and their families: a systematic review
Alzehr, A., Hulme, C., Spencer, A., & Morgan-Trimmer, S. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06913-x · Cited by 59
“The influence of the Australian healthcare system on cancer expenses has also been discussed in recent research [42] where cancer patients who had private insurance experienced higher economic burdens than those who relied on government-funded hospitals as a result of high co-payments (e.”
BackgroundPaul, C. L., Warren, G., Vinod, S., Meiser, B., Stone, E., Barker, D., White, K., McLennan, J., Day, F., McCarter, K., et al. (2021) · Implementation Science · doi:10.1186/s13012-021-01092-5 · Cited by 10
Metadata
- Authors
- Gordon, L. G., Walker, S. M., Mervin, M. C., Lowe, A., Smith, D. P., Gardiner, R. A., & Chambers, S. K.
- Venue
- European Journal of Cancer Care
- Publisher
- Wiley
- Published
- 2015-10-01
- Volume
- 26
- Issue
- 1
- Pages
- e12392
- ISSN
- 0961-5423 (ISSN-L)
- OpenAlex
- W2164451159
- Cited by
- 98
- References
- 0
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.